Aptus Pharma
- Market cap
- ₹ 843 Cr.
- P/E
- 106x
- P/B
- 36.84x
- 52-week range
- 49.24 – 510.9
- ROE
- 30%
- ROCE
- 30%
- Dividend yield
- 0%
- Debt / equity
- 0.31
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE SME
About
Aptus Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing a range of medicine solutions which include Anti-Infectives, Antacids and PPI, G.I. Medicines, Anti-Allergic and Respiratory Medicine, Nutritional Supplements, Anti-Inflammatory and Pain Management, Neuro-Psychiatric Medicine, Lipid Lowering Medicine, Anti-Hypertensives and Cardiovascular Medicine, Antidiabetic Medicine, and Consumer Care. Its divisions include Aptus Pharma, Aptus CD Care, Aptus WellCare, and Aptus Global. Its brands include Chilkul, Koltus, Telbira, and Aptirub. Its products include APBILE-150, APBILE-300, APORA 5 CREAM, APTICHYM-FORTE, APTIDA-10, APTIDA-M, APTIDOL-MR, APTIDOX-L, APTIFRESH, APTIFRESH-EC, APTIFRESH-FM, APTIFRESH-LE, APTIFRESH-MD, APTIFRESH-MW, APTIGLIM-M1 FORTE, APTIGLIM-M1 PR, APTIGLIM-M2 FORTE, APTIGLIM-M2 SR, among others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Aptus Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)106 against a typical 33.2: pricier than most peers (1st = cheapest).194th of 220
- Share price, 3 months+77.9% against a typical −1.8%.6th of 200
- Size₹ 842.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).90th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 10 | 15 | 14 | 32 |
| Expenses | 8 | 12 | 11 | 28 |
| Operating Profit | 2 | 3 | 3 | 5 |
| OPM % | 20.3% | 19.4% | 20.4% | 14% |
| Other Income | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 2 | 2 | 4 |
| Tax % | 25.6% | 26.2% | 25.5% | 28.6% |
| Net Profit | 1 | 2 | 2 | 3 |
| EPS in Rs | 5.24 | 1.43 | 1.02 | 1.67 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 50%
- TTM
- 90%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 190%
- TTM
- 49%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 41%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Aptus Pharma | ₹ 462.70 | ₹ 843 Cr. | 106x | 36.8x | 30% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Ghanshyam Vinubhai Pansuriya
- Chief Executive Officer
- Kapilbhai Hasmukhbhai Chandarana
- Chief Financial Officer
- Mohini Hardikbhai Gandhi
- Company Secretary, Compliance Officer
- Tejash Maheshchandra Hathi
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.